Developer docs
API playgroundTry for free, no card

Search company profiles

Intelligent Retinal Imaging Systems

Full company profile

uuid0002z54

Namestring
Intelligent Retinal Imaging Systems
Legal namestring
Intelligent Retinal Imaging Systems, LLC
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Intelligent Retinal Imaging Systems (IRIS) is a Pensacola, Florida-based healthcare technology company founded in 2012 that operates a cloud-based, camera-agnostic teleretinal screening platform for the early detection of diabetic retinopathy. Its core product is an FDA Class II cleared software platform (21 CFR Part 11 compliant) that integrates with Epic and other EMR systems, applies a proprietary image enhancement algorithm to fundus images, and routes cases to the IRIS Reading Center — a remote interpretation service staffed by board-certified retina specialists — for diagnosis of diabetic retinopathy, macular edema, glaucoma, and other retinal pathologies. The non-mydriatic workflow enables primary care providers and non-specialist staff to complete screenings in under 15 minutes without pupil dilation, eliminating the need for specialist referrals for the majority of cases.

IRIS generates revenue primarily through annual subscription SaaS contracts with healthcare organizations, with pricing bundled to include software licensing, image processing, remote specialist interpretation, EMR integration, and training. Hardware (tabletop or handheld fundus cameras) is sold or rented separately, and customers — primarily hospitals and health systems, FQHCs, health plans, HRA organizations, primary care practices, and labs/pharmacies — also capture downstream value through improved HEDIS/Star ratings and value-based care incentives. Go-to-market is dual-pronged: a consultative enterprise field-sales motion with a 90-day implementation timeline, and a channel partnership model in which HRA and in-home health evaluation partners (notably HealPros) deploy IRIS-trained technicians in non-clinical settings.

Following its 2025 acquisition by Topcon Healthcare, IRIS operates as an affiliate of the Topcon group from its Pensacola headquarters and is being integrated into Topcon's Harmony cloud platform and "Healthcare from the Eye" initiative, with stated expansion into diagnostic modules for cardiovascular disease, chronic kidney disease, and early Alzheimer's detection. Across more than 650 healthcare organizations, IRIS has enabled over 1.8 million screenings and identified more than 279,000 cases of diabetic retinopathy, with documented customer outcomes including screening compliance improvements from approximately 30% to over 80% at deployed health systems and quality score lifts from 30% to nearly 90%.

Short descriptiontext

IRIS is a Pensacola-based teleretinal screening platform enabling healthcare organizations to perform FDA-cleared diabetic retinopathy screenings using cloud-based, camera-agnostic software with proprietary image enhancement and remote specialist interpretation, serving 650+ providers as an affiliate of Topcon Healthcare.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPensacola, United States
HQ citystring
Pensacola
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retinal screening software, diabetic retinopathy screening, teleretinal imaging platform, teleophthalmology services, fundus image enhancement
Industry3 codes
PRIMARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
NAICS code1 code
  • Diagnostic Imaging Centers621512
SIC code1 code
  • Optical Instruments & Lenses3827
Product category
Teleretinal Screening Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Subscription SaaS Platform Fee
TypeSubscription Recurring
Description

IRIS operates as a subscription-based software-as-a-service platform where healthcare organizations pay for access to the IRIS retinal screening platform, software, cloud hosting, and the IRIS Reading Center interpretation services. The subscription model includes software licensing, image processing, remote grading by board-certified specialists, and EMR integration. Implementation and training services are bundled with the subscription.

retinalscreenings.com
2Hardware (Fundus Camera) Sales/Rental
TypeHardware Sales
Description

IRIS recommends and facilitates the procurement of fundus cameras (both tabletop and handheld) for client organizations. Camera hardware costs are separate from the software subscription, with IRIS offering camera-agnostic compatibility so clients can choose hardware that fits their budget and setting.

retinalscreenings.com
3Value-Based Care Financial Incentives
TypeManaged Services
Description

Healthcare organizations implementing IRIS can generate financial returns through value-based contracts, payer incentives, HEDIS/quality bonuses, and HCC/RAF adjustments by improving screening compliance rates and closing care gaps in diabetic patient populations.

retinalscreenings.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Enterprise subscription for healthcare organizations
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing is quote-based. Includes cloud platform access, proprietary image enhancement, IRIS Reading Center interpretation, EMR integration, training, and ongoing support. Additional costs for fundus camera hardware (tabletop or handheld) purchased or rented separately.

retinalscreenings.com
2Payer/Health Plan and HRA organization programs
ModelSubscriptionBilling cadenceAnnual
Notes

At-home and mobile screening programs facilitated through HRA organizations and health plans. IRIS Reading Center gradeability rates are critical for in-home market. Financial returns through HEDIS/Star rating improvements and value-based contract incentives.

retinalscreenings.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

IRIS provides a cloud-based, camera-agnostic teleretinal screening platform that enables healthcare organizations to perform non-mydriatic diabetic retinopathy and other retinal pathology screenings at the point of care using compatible fundus cameras. The platform applies a proprietary image enhancement algorithm, integrates with EMR systems such as Epic, and routes images to the IRIS Reading Center, where board-certified retina specialists deliver diagnostic interpretations back into the patient's electronic health record. IRIS also facilitates fundus camera procurement and offers implementation, training, and ongoing program support to healthcare organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Gradability rate of 92-96%, approximately 20% above industry standard where competitors average 20-30% ungradeable rates
+5 more records
Product overview1 text field

IRIS (Intelligent Retinal Imaging Systems) offers a unified cloud-based teleretinal screening platform designed to eliminate preventable blindness from diabetic retinopathy. The core IRIS Retinal Screening Platform integrates with various fundus cameras and EMR systems, utilizing the proprietary Image Enhancement Technology to process retinal images. The IRIS Reading Center provides remote interpretation by board-certified specialists, while the IRIS Portal delivers diagnostic results and analytics. IRIS University provides training resources, all accessible through a single integrated workflow enabling primary care providers to perform diabetic retinopathy screenings at point-of-care.

Product and service3 records
1IRIS Retinal Screening Platform
CategoryTeleretinal screening software
Description

Cloud-based, camera-agnostic teleretinal screening platform that enables healthcare providers to capture, enhance, and diagnose diabetic retinopathy and other retinal pathologies at the point of care; integrates with EMR systems such as Epic and is delivered as a subscription.

2IRIS Reading Center (IRC)
CategoryDiagnostic interpretation services
Description

Remote teleophthalmology diagnostic service staffed by board-certified retina specialists who review and interpret retinal images captured on the IRIS platform, returning graded reports to the client's EMR for diabetic retinopathy, macular edema, glaucoma, AMD, and cataract identification.

3IRIS University (IRIS-U)
CategoryTraining and education platform
Description

Branded eLearning/Learning Management System that delivers virtual training modules customized to the client's camera type and workflow, covering pre-implementation curriculum and ongoing training resources accessible through the IRIS Portal.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Topcon Healthcare, a global leader in digital health and ocular data solutions, acquired Intelligent Retinal Imaging Systems in 2025. The acquisition marks a major step in enhancing Topcon Healthcare's presence in primary care and reinforces connected, data-driven care. IRIS is being integrated into Topcon's Healthcare from the Eye initiative and Harmony cloud-based connected care platform. IRIS continues operating from its Pensacola headquarters as an affiliate of Topcon Healthcare. The acquisition enables bidirectional care coordination between primary care providers and eye care providers, and supports IRIS's expansion into diagnostic modules for cardiovascular disease, chronic kidney disease, and early Alzheimer's detection.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eyenuk is a direct competitor offering FDA-cleared autonomous AI for diabetic retinopathy screening (EyeArt), serving primary care, health plans, and at-risk populations with a similar point-of-care screening thesis as IRIS.

TypeDirect peer
Description

Digital Diagnostics built IDx-DR, an FDA-authorized autonomous AI diagnostic system for diabetic retinopathy, competing head-to-head with IRIS in primary-care point-of-care DR screening programs.

TypeDirect peer
Description

RetinaVue by Hillrom/Welch Allyn offers a teleretinal screening solution combining handheld fundus cameras with reading-center and EMR integration — directly comparable to IRIS's end-to-end model used by FQHCs and health systems.

TypeBroad incumbent
Description

Topcon Healthcare is IRIS's strategic acquirer and operates a broad portfolio of ophthalmic diagnostic devices plus the Harmony cloud platform; its Healthcare from the Eye initiative now houses IRIS, making it both parent and adjacent competitor in connected ocular care.

TypeBroad incumbent
Description

ZEISS is a global incumbent in ophthalmic imaging (including fundus and OCT systems) and operates across primary-care and specialty eye-care workflows; its FORUM/ZEISS Retina Workflow overlaps with the diagnostic-imaging portion of IRIS's value chain.

TypeBroad incumbent
Description

Nidek manufactures fundus cameras, OCT, and other ophthalmic diagnostic devices that integrate into DR screening programs; as a hardware incumbent, it is comparable to IRIS's camera-agnostic integration strategy on the device side.

TypeEmerging player
Description

Optomed builds handheld fundus cameras and is moving into AI-driven screening workflows for primary care, competing with one half of IRIS's stack (hardware) while partnering on the other (software/grading).

TypeEmerging player
Description

Remidio produces portable/AI-enabled retinal cameras and screening software for DR; IRIS has an existing commercial partnership with Remidio announced in 2017 to bring iOS-based retinal imaging into the U.S. market.

TypeRegional player
Description

Aravind operates large-scale tele-ophthalmology and DR screening programs in India using high-volume, low-cost workflows, addressing the same DR blindness-prevention mission as IRIS but in a different geographic and economic context.

TypeEmerging player
Description

Airdoc builds autonomous AI for retinal and systemic disease screening from fundus images; it competes with IRIS's reading-center and AI-enhancement capabilities in adjacent markets and is an emerging global peer in eye-as-biomarker diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intelligent Retinal Imaging Systems

Teleretinal Screening Softwareretinalscreenings.com

IRIS is a Pensacola-based teleretinal screening platform enabling healthcare organizations to perform FDA-cleared diabetic retinopathy screenings using cloud-based, camera-agnostic software with proprietary image enhancement and remote specialist interpretation, serving 650+ providers as an affiliate of Topcon Healthcare.

What Intelligent Retinal Imaging Systems does

Intelligent Retinal Imaging Systems (IRIS) is a Pensacola, Florida-based healthcare technology company founded in 2012 that operates a cloud-based, camera-agnostic teleretinal screening platform for the early detection of diabetic retinopathy. Its core product is an FDA Class II cleared software platform (21 CFR Part 11 compliant) that integrates with Epic and other EMR systems, applies a proprietary image enhancement algorithm to fundus images, and routes cases to the IRIS Reading Center — a remote interpretation service staffed by board-certified retina specialists — for diagnosis of diabetic retinopathy, macular edema, glaucoma, and other retinal pathologies. The non-mydriatic workflow enables primary care providers and non-specialist staff to complete screenings in under 15 minutes without pupil dilation, eliminating the need for specialist referrals for the majority of cases.

IRIS generates revenue primarily through annual subscription SaaS contracts with healthcare organizations, with pricing bundled to include software licensing, image processing, remote specialist interpretation, EMR integration, and training. Hardware (tabletop or handheld fundus cameras) is sold or rented separately, and customers — primarily hospitals and health systems, FQHCs, health plans, HRA organizations, primary care practices, and labs/pharmacies — also capture downstream value through improved HEDIS/Star ratings and value-based care incentives. Go-to-market is dual-pronged: a consultative enterprise field-sales motion with a 90-day implementation timeline, and a channel partnership model in which HRA and in-home health evaluation partners (notably HealPros) deploy IRIS-trained technicians in non-clinical settings.

Following its 2025 acquisition by Topcon Healthcare, IRIS operates as an affiliate of the Topcon group from its Pensacola headquarters and is being integrated into Topcon's Harmony cloud platform and "Healthcare from the Eye" initiative, with stated expansion into diagnostic modules for cardiovascular disease, chronic kidney disease, and early Alzheimer's detection. Across more than 650 healthcare organizations, IRIS has enabled over 1.8 million screenings and identified more than 279,000 cases of diabetic retinopathy, with documented customer outcomes including screening compliance improvements from approximately 30% to over 80% at deployed health systems and quality score lifts from 30% to nearly 90%.

Intelligent Retinal Imaging Systems firmographics

Firmographics
Name
Intelligent Retinal Imaging Systems
Legal name
Intelligent Retinal Imaging Systems, LLC
Website
https://retinalscreenings.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
11–50 employees
Short description
IRIS is a Pensacola-based teleretinal screening platform enabling healthcare organizations to perform FDA-cleared diabetic retinopathy screenings using cloud-based, camera-agnostic software with proprietary image enhancement and remote specialist interpretation, serving 650+ providers as an affiliate of Topcon Healthcare.
Ownership category
akta.pro rank

Intelligent Retinal Imaging Systems industry classification

Industry
Product category
Teleretinal Screening Software
NAICS
Diagnostic Imaging Centers (621512)
SIC
Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)

Keywords

  • Retinal screening software
  • Diabetic retinopathy screening
  • Teleretinal imaging platform
  • Teleophthalmology services
  • Fundus image enhancement

Where Intelligent Retinal Imaging Systems is headquartered

Location

Headquarters

HQ city
Pensacola
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Intelligent Retinal Imaging Systems business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Subscription SaaS Platform Fee: IRIS operates as a subscription-based software-as-a-service platform where healthcare organizations pay for access to the IRIS retinal screening platform, software, cloud hosting, and the IRIS Reading Center interpretation services. The subscription model includes software licensing, image processing, remote grading by board-certified specialists, and EMR integration. Implementation and training services are bundled with the subscription.
  2. Hardware (Fundus Camera) Sales/Rental: IRIS recommends and facilitates the procurement of fundus cameras (both tabletop and handheld) for client organizations. Camera hardware costs are separate from the software subscription, with IRIS offering camera-agnostic compatibility so clients can choose hardware that fits their budget and setting.
  3. Value-Based Care Financial Incentives: Healthcare organizations implementing IRIS can generate financial returns through value-based contracts, payer incentives, HEDIS/quality bonuses, and HCC/RAF adjustments by improving screening compliance rates and closing care gaps in diabetic patient populations.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise subscription for healthcare organizations
SubscriptionAnnualPayer/Health Plan and HRA organization programs

Go-to-market motion2 records

Distribution channels2 records

Marketing channels9 records

Intelligent Retinal Imaging Systems product offering

Product offering

Core offering

IRIS provides a cloud-based, camera-agnostic teleretinal screening platform that enables healthcare organizations to perform non-mydriatic diabetic retinopathy and other retinal pathology screenings at the point of care using compatible fundus cameras. The platform applies a proprietary image enhancement algorithm, integrates with EMR systems such as Epic, and routes images to the IRIS Reading Center, where board-certified retina specialists deliver diagnostic interpretations back into the patient's electronic health record. IRIS also facilitates fundus camera procurement and offers implementation, training, and ongoing program support to healthcare organizations.

Product overview

IRIS (Intelligent Retinal Imaging Systems) offers a unified cloud-based teleretinal screening platform designed to eliminate preventable blindness from diabetic retinopathy. The core IRIS Retinal Screening Platform integrates with various fundus cameras and EMR systems, utilizing the proprietary Image Enhancement Technology to process retinal images. The IRIS Reading Center provides remote interpretation by board-certified specialists, while the IRIS Portal delivers diagnostic results and analytics. IRIS University provides training resources, all accessible through a single integrated workflow enabling primary care providers to perform diabetic retinopathy screenings at point-of-care.

Differentiator

Problem solved

Functional benefit

Products and services

  • IRIS Retinal Screening Platform Cloud-based, camera-agnostic teleretinal screening platform that enables healthcare providers to capture, enhance, and diagnose diabetic retinopathy and other retinal pathologies at the point of care; integrates with EMR systems such as Epic and is delivered as a subscription.
  • IRIS Reading Center (IRC) Remote teleophthalmology diagnostic service staffed by board-certified retina specialists who review and interpret retinal images captured on the IRIS platform, returning graded reports to the client's EMR for diabetic retinopathy, macular edema, glaucoma, AMD, and cataract identification.
  • IRIS University (IRIS-U) Branded eLearning/Learning Management System that delivers virtual training modules customized to the client's camera type and workflow, covering pre-implementation curriculum and ongoing training resources accessible through the IRIS Portal.

Quantifiable outcome

  • Gradability rate of 92-96%, approximately 20% above industry standard where competitors average 20-30% ungradeable rates
  • +5 more outcomes

Companies that use Intelligent Retinal Imaging Systems

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Intelligent Retinal Imaging Systems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature6 records

Intelligent Retinal Imaging Systems partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Topcon HealthcareflagshipStrategic or Co-development Partner · 1 January 2025Topcon Healthcare, a global leader in digital health and ocular data solutions, acquired Intelligent Retinal Imaging Systems in 2025. The acquisition marks a major step in enhancing Topcon Healthcare's presence in primary care and reinforces connected, data-driven care. IRIS is being integrated into Topcon's Healthcare from the Eye initiative and Harmony cloud-based connected care platform. IRIS continues operating from its Pensacola headquarters as an affiliate of Topcon Healthcare. The acquisition enables bidirectional care coordination between primary care providers and eye care providers, and supports IRIS's expansion into diagnostic modules for cardiovascular disease, chronic kidney disease, and early Alzheimer's detection.

Scale indicators9 records

Recent moves5 records

Expansion highlights5 records

Intelligent Retinal Imaging Systems competitors and assessment

Company assessment

Direct peers

  • Eyenuk (EyeArt AI): Eyenuk is a direct competitor offering FDA-cleared autonomous AI for diabetic retinopathy screening (EyeArt), serving primary care, health plans, and at-risk populations with a similar point-of-care screening thesis as IRIS.
  • Digital Diagnostics (IDx-DR): Digital Diagnostics built IDx-DR, an FDA-authorized autonomous AI diagnostic system for diabetic retinopathy, competing head-to-head with IRIS in primary-care point-of-care DR screening programs.
  • RetinaVue (by Hillrom / Baxter / Welch Allyn): RetinaVue by Hillrom/Welch Allyn offers a teleretinal screening solution combining handheld fundus cameras with reading-center and EMR integration — directly comparable to IRIS's end-to-end model used by FQHCs and health systems.

Broad incumbents

  • Topcon Healthcare (parent): Topcon Healthcare is IRIS's strategic acquirer and operates a broad portfolio of ophthalmic diagnostic devices plus the Harmony cloud platform; its Healthcare from the Eye initiative now houses IRIS, making it both parent and adjacent competitor in connected ocular care.
  • ZEISS Medical Technology: ZEISS is a global incumbent in ophthalmic imaging (including fundus and OCT systems) and operates across primary-care and specialty eye-care workflows; its FORUM/ZEISS Retina Workflow overlaps with the diagnostic-imaging portion of IRIS's value chain.
  • Nidek: Nidek manufactures fundus cameras, OCT, and other ophthalmic diagnostic devices that integrate into DR screening programs; as a hardware incumbent, it is comparable to IRIS's camera-agnostic integration strategy on the device side.

Emerging players

  • Optomed: Optomed builds handheld fundus cameras and is moving into AI-driven screening workflows for primary care, competing with one half of IRIS's stack (hardware) while partnering on the other (software/grading).
  • Remidio Innovative Solutions: Remidio produces portable/AI-enabled retinal cameras and screening software for DR; IRIS has an existing commercial partnership with Remidio announced in 2017 to bring iOS-based retinal imaging into the U.S. market.
  • Airdoc: Airdoc builds autonomous AI for retinal and systemic disease screening from fundus images; it competes with IRIS's reading-center and AI-enhancement capabilities in adjacent markets and is an emerging global peer in eye-as-biomarker diagnostics.

Regional players

  • Aravind Eye Hospital System: Aravind operates large-scale tele-ophthalmology and DR screening programs in India using high-volume, low-cost workflows, addressing the same DR blindness-prevention mission as IRIS but in a different geographic and economic context.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Intelligent Retinal Imaging Systems social profiles

Digital presence

Intelligent Retinal Imaging Systems compliance and trust

Trust signal

Compliance1 record

Intelligent Retinal Imaging Systems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intelligent Retinal Imaging Systems leadership team

Management profile

Number of profiles

Profiles3 records

Intelligent Retinal Imaging Systems funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intelligent Retinal Imaging Systems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intelligent Retinal Imaging Systems

What does Intelligent Retinal Imaging Systems do?

IRIS provides a cloud-based, camera-agnostic teleretinal screening platform that enables healthcare organizations to perform non-mydriatic diabetic retinopathy and other retinal pathology screenings at the point of care using compatible fundus cameras. The platform applies a proprietary image enhancement algorithm, integrates with EMR systems such as Epic, and routes images to the IRIS Reading Center, where board-certified retina specialists deliver diagnostic interpretations back into the patient's electronic health record. IRIS also facilitates fundus camera procurement and offers implementation, training, and ongoing program support to healthcare organizations.

Is Intelligent Retinal Imaging Systems a public or private company?

Intelligent Retinal Imaging Systems is a private company. It is classified as corporate owned and is currently acquired.

When was Intelligent Retinal Imaging Systems founded?

Intelligent Retinal Imaging Systems was founded in 2012. It employs 11 to 50 people.

Where is Intelligent Retinal Imaging Systems based?

Intelligent Retinal Imaging Systems is headquartered in Pensacola, United States, in the North America region.

How does Intelligent Retinal Imaging Systems make money?

Three revenue lines are on record. Subscription SaaS Platform Fee is the primary driver. The others are hardware (Fundus Camera) Sales/Rental and value-Based Care Financial Incentives.

Who are Intelligent Retinal Imaging Systems's main competitors?

Direct peers on record are Eyenuk (EyeArt AI), Digital Diagnostics (IDx-DR) and RetinaVue (by Hillrom / Baxter / Welch Allyn). Broad incumbents are Topcon Healthcare (parent), ZEISS Medical Technology and Nidek. Emerging players are Optomed, Remidio Innovative Solutions and Airdoc. Aravind Eye Hospital System is listed as a regional player.

Does Intelligent Retinal Imaging Systems have an API?

No public API is recorded for Intelligent Retinal Imaging Systems.

What industry is Intelligent Retinal Imaging Systems in?

Intelligent Retinal Imaging Systems's product category is Teleretinal Screening Software. Its primary akta.pro industry code is HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers, with a secondary code of HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography). Its NAICS code is 621512 and its SIC code is 3827.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
RetinalscreeningsTopcon Healthcare Acquires Intelligent Retinal Imaging Systems to Enhance Connected Care Across Primary and Eye CareTopcon Healthcare acquired IRIS, a U.S. cloud-based retinal screening platform, to expand its primary care presence. IRIS has enabled over 1.8 million screenings and identified 279,000 diabetic retinopathy cases. The integration will enhance Topcon's Harmony platform and support bidirectional care coordination.Eyes On EyecareTopcon acquires Intelligent Retinal Imaging SystemsTopcon Healthcare, Inc. has acquired Intelligent Retinal Imaging Systems (IRIS), the developer of an FDA-cleared cloud-based platform for AI-driven diabetic teleretinal screening. Topcon plans to integrate IRIS technology into its Harmony platform to strengthen coordination between eye care providers and primary care physicians within its 'Healthcare from the Eye' initiative. The acquisition aims to expand early detection of ocular and systemic diseases, leveraging IRIS's existing network of over 650 healthcare organizations in the United States.Eyes On EyecareTopcon Healthcare acquires Intelligent Retinal Imaging Systems to enhance connected care across primary and eye careTopcon Healthcare acquired Intelligent Retinal Imaging Systems (IRIS), a U.S. cloud-based retinal screening pioneer. The acquisition integrates IRIS into Topcon's Harmony platform to strengthen primary-care eye care coordination. IRIS has enabled over 1.8 million screenings and identified more than 279,000 diabetic retinopathy cases.PR NewswireIRIS Reaches 1 Million LivesIntelligent Retinal Imaging Systems (IRIS) announced it has performed one million diabetic retinal exams, a milestone reached in January 2023 since its first exam in June 2013. The company identified 130,000 cases of sight-threatening pathology among these patients, highlighting the clinical value of its screening services across over 600 client locations.PR NewswireIntelligent Retinal Imaging Systems (IRIS) Partners with Remidio Innovative Solutions Pvt Ltd to Provide Affordable Early Detection Systems for Diabetic Eye DiseaseIRIS announced a partnership with Remidio to bring a smartphone-based non-mydriatic fundus camera to the U.S. market, combining it with IRIS software for diabetic retinal disease detection. The Remidio device has been validated against high-end desktop systems and offers AI-ready image grading. The partnership aims to reduce diabetes management costs by 30% through early detection.PR NewswireIRIS Telemedicine Solution Identifies 50,000th Patient with Sight-Threatening Retinal DiseaseIntelligent Retinal Imaging Systems (IRIS) announced that its telemedicine platform has identified its 50,000th patient with potential sight-threatening retinal diseases since its launch in 2013. This milestone reflects IRIS's role in substantially aiding early detection and treatment of conditions that could lead to blindness, with a goal to double the number of identified patients to 100,000 by the end of next year. The article highlights the increasing prevalence of diabetes and the importance of regular retinal examinations in preventing vision loss.PR NewswireIRIS Celebrates 5th Anniversary with More Than 335,000 Patient Exams Performed for Sight-Threatening Retinal DiseaseIntelligent Retinal Imaging Systems (IRIS) announced that its cloud-based diagnostic platform has performed over 335,000 patient exams for diabetic retinopathy since its launch in 2013. The company also reported significant growth metrics, including doubling its employee headcount and exceeding sales targets for the first three quarters of 2018.PR NewswireGateway Medical Associates Closes Care Gaps and Improves Patient Outcomes with IRIS Diabetic Retinal Exam Telemedicine ProgramPhysician-owned medical practice Gateway Medical Associates implemented Intelligent Retinal Imaging Systems' (IRIS) diabetic retinopathy telemedicine solution in October 2016, examining 4,810 patients in the first year and identifying 678 patients (14%) with diabetic retinopathy who would otherwise have gone undiagnosed. The implementation increased the practice's diabetic retinal exam compliance rate from 37% to 85%, enabling Gateway to achieve HEDIS compliance and quality outcomes while generating increased revenue from quality incentives. The program has referred 203 patients with sight-threatening disease to ophthalmologists and retinal specialists, creating a referral stream that did not previously exist for those practices.FinSMEsIntelligent Retinal Imaging Systems Raises Series B Growth FundingIntelligent Retinal Imaging Systems closed a Series B round led by Ballast Point Ventures, with participation from Providence Ventures and CoxHealth. The undisclosed amount will fund business expansion, and new board members were added. The company's retinal telemedicine platform is deployed at 94 health systems across 28 states.GlobeNewswireDIAGNOS Inc.: CARA Licensing Agreement of $700,000 With Intelligent Retina Imaging Systems Inc. for a 3 Year Period.DIAGNOS signed a non-exclusive licensing agreement with Intelligent Retina Imaging Systems (IRIS) for its CARA tele-ophthalmology platform. IRIS will pay DIAGNOS $700,000 over three years to use CARA in the Pensacola Florida region and surrounding states. The deal aims to improve diabetic vision screening and is the first step in a longer U.S. sales process.